Mifepristone
In April 2023, during the Alliance for Hippocratic Medicine v. US Food and Drug Administration lawsuit, federal district judge Matthew J. Kacsmaryk issued a preliminary injunction suspending the approval of mifepristone. This ruling would come into effect a week later.  Also in April 2023, in a lawsuit brought by 17 U.S. states and the District of Columbia, federal district judge Thomas O. Rice issued a temporary injunction that the FDA should not reduce access to mifepristone in these states and the district. Because there are two different laws in two different parts of the United States, it is likely that the U.S. Supreme Court will have to decide on the matter